Morgan Stanley analyst Judah Frommer initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Overweigh

The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q

Q32 Bio (NASDAQ:QTTB) reported quarterly losses of $(0.44) per share which beat the analyst consensu

-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; ad

The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical res

Top Wall Street analysts changed their outlook on top names. For a complete view, see analyst rating

HC Wainwright & Co. analyst Joseph Pantginis maintains Q32 Bio (NASDAQ:QTTB) with a Buy and r

Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCel

Does Q32 Bio (QTTB) have what it takes to be a top stock pick for momentum investors? Let's find out

Q32 Bio's Part B data showed meaningful hair regrowth in severe alopecia areata, including for JAK-e

Q32 Bio (QTTB) stock slips after pricing a $200M public offering at $18.25. Get the details on the d

The consensus price target hints at an 80.1% upside potential for Q32 Bio (QTTB). While empirical re

WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical st

Q32 Bio (NASDAQ:QTTB) has outperformed the market over the past 5 years by 11.82% on an annualized b

U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-m

The biotech is advancing a potential treatment for a common autoimmune disease.

Q32 Bio Inc. (NASDAQ:QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on de

Q32 Bio upgraded to "Strong Buy" after positive phase 2a SIGNAL-AA results for bempikibart in severe

WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical st

Wells Fargo analyst Derek Archila upgrades Q32 Bio (NASDAQ:QTTB) from Equal-Weight to Overweight

Q32 Bio (QTTB) shares doubled on Monday as the clinical-stage biotech firm announced positive 36-wee

Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session

US stocks dip, Nasdaq falls 1%. Dow down 0.34%. Energy shares up 2.1%, tech down 1.2%. Micron Tech d

Q32 Bio NASDAQ: QTTB reported positive 36-week top-line results from Part B of its SIGNAL-AA Phase 2

Oppenheimer analyst Jay Olson maintains Q32 Bio (NASDAQ:QTTB) with a Outperform and raises the pr

US stocks mixed, Dow up 100 points. Energy up 2.1%, tech down 1.1%. LogProstyle Inc shares rise on e

Q32 Bio Inc. (NASDAQ:QTTB) stock is trading higher on Monday after the clinical-stage biotechnology

Q32 Bio reported positive Phase 2a data for bempikibart in severe alopecia areata, showing hair regr

U.S. stock futures were mixed on Monday, as the Dow Jones index advanced, while the Nasdaq 100 and S

Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke

QTTB: 82% | Q32 Bio shares are trading higher after the company it will report 36-week topline resul

-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent redu

-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent redu

Gainers: Q32 Bio up 29.6%, Mint up 75.8%, Fast Track up 58.2%, eLong up 33.4%, Sobr Safe up 29.2%, E

U.S. stock futures down today, FB Financial, Smith Micro Software, LogProstyle, Veraxa Biotech, and

Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-mark

Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on de

-- Conference call to be held Monday, July 13 th at 8:00 a.m. E.T. -- WALTHAM, Mass.

Q32 Bio ($QTTB) jumps in premarket trading after securing a $55M private placement to fund its autoi

I initiate Q32 Bio (QTTB) at 'Buy' due to advancing bempikibart for Alopecia Areata and strong upcom

Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology

WALTHAM, Mass., May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a

The average of price targets set by Wall Street analysts indicates a potential upside of 145.7% in Q

Analysts change outlook on top names. Check out ratings page for upgrades, downgrades, and initiatio

Mizuho analyst Joseph Catanzaro initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Outperform rat

The consensus price target hints at a 163.4% upside potential for Q32 Bio (QTTB). While empirical re

HC Wainwright & Co. analyst Joseph Pantginis reiterates Q32 Bio (NASDAQ:QTTB) with a Buy and